Neumora Therapeutics (NMRA) Accumulated Expenses (2022 - 2026)
Neumora Therapeutics (NMRA) posted quarterly Accumulated Expenses of $24.8 million for Q1 2026, down 5.73% year-over-year from $26.3 million in Q1 2025, and down 13.97% quarter-over-quarter from $28.8 million in Q4 2025.
Neumora Therapeutics (NMRA) Accumulated Expenses (2022 - 2026) Analysis & Trends
Neumora Therapeutics' Accumulated Expenses history runs 5 years deep, the most recent figure standing at $24.8 million for Q1 2026.
- In Q1 2026, Accumulated Expenses fell 5.73% year-over-year to $24.8 million; the TTM figure through Mar 2026 stood at $24.8 million (down 5.73% YoY), while the FY2025 annual figure was $28.8 million, up 188.6% from the prior year.
- Accumulated Expenses for Q1 2026 stood at $24.8 million, down from $28.8 million in the prior quarter.
- The five-year high for Accumulated Expenses was $28.8 million in Q4 2025, with the low at $4.7 million in Q1 2024.
- The 5-year median for Accumulated Expenses is $10.0 million (2023), against an average of $15.3 million.
- The sharpest annual moves came in 2024 and 2025: Accumulated Expenses plunged 62.12% in 2024, then soared 463.78% in 2025.
- Neumora Therapeutics' Accumulated Expenses stood at $8.4 million in 2022, then advanced by 19.18% to $10.0 million in 2023, then dropped by 0.36% to $10.0 million in 2024, then surged by 188.6% to $28.8 million in 2025, then decreased by 13.97% to $24.8 million in 2026.
- Business Quant data shows NMRA's Accumulated Expenses at $24.8 million in Q1 2026, $28.8 million in Q4 2025, and $25.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Neumora Therapeutics | 296.45 Mn | 296.45 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 24.77 Mn |
| Dec 31, 2025 | 28.79 Mn |
| Sep 30, 2025 | 24.98 Mn |
| Jun 30, 2025 | 6.65 Mn |
| Mar 31, 2025 | 26.27 Mn |
| Dec 31, 2024 | 9.98 Mn |
| Sep 30, 2024 | 8.84 Mn |
| Jun 30, 2024 | 7.46 Mn |
| Mar 31, 2024 | 4.66 Mn |
| Dec 31, 2023 | 10.01 Mn |
| Sep 30, 2023 | 23.35 Mn |
| Dec 31, 2022 | 8.40 Mn |